RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

Core Insights - RenovoRx, Inc. announced the acceptance of a clinical data abstract for presentation at the 2026 Society of Interventional Radiology Annual Scientific Meeting, focusing on the TAMP™ therapy platform for treating locally advanced pancreatic cancer [1][2] Company Overview - RenovoRx is a life sciences company specializing in targeted oncology therapies and has developed the RenovoCath, an FDA-cleared drug-delivery device [5] - The company aims to address high unmet medical needs in cancer treatment through innovative solutions [5] Clinical Research and Development - The abstract titled "What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer" explores the efficacy of local, targeted intra-arterial chemotherapy delivery using the TAMP therapy platform [2][3] - The research evaluates the role of metabolic imaging (FDG PET/CT) in assessing therapeutic activity in patients with refractory pancreatic cancer [2] Product Details - RenovoCath is designed for the isolation of blood flow and delivery of therapeutic agents directly to tumor sites, potentially improving treatment efficacy while minimizing systemic toxicity [4][5] - The device is indicated for temporary vessel occlusion and has received Orphan Drug Designation for pancreatic and bile duct cancers, granting seven years of market exclusivity upon FDA approval [8] Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath devices [6] - The company generated approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025, with several customers placing repeat orders [6] Ongoing Trials - The company is evaluating a novel drug-device combination product candidate, intra-arterial gemcitabine delivered via RenovoCath, in the Phase III TIGeR-PaC trial [7] - This candidate is currently under investigation and has not yet been approved for commercial sale [8]